Xeltis
11
2
5
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
9.1%
1 terminated/withdrawn out of 11 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)
Role: lead
Xeltis Hemodialysis Access Graft (aXess) US Study
Role: lead
Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study
Role: lead
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
Role: lead
Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit Early Feasibility Study
Role: lead
First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft
Role: lead
Xeltis Hemodialysis Access (aXess) Conduit: aXess-E Study
Role: lead
Xeltis Pulmonary Valved Conduit Safety and Performance Study
Role: lead
Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction
Role: lead
Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis
Role: lead
Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection
Role: lead
All 11 trials loaded